BR112022016653A2 - Pld para uso em combinação no tratamento de coronavírus - Google Patents

Pld para uso em combinação no tratamento de coronavírus

Info

Publication number
BR112022016653A2
BR112022016653A2 BR112022016653A BR112022016653A BR112022016653A2 BR 112022016653 A2 BR112022016653 A2 BR 112022016653A2 BR 112022016653 A BR112022016653 A BR 112022016653A BR 112022016653 A BR112022016653 A BR 112022016653A BR 112022016653 A2 BR112022016653 A2 BR 112022016653A2
Authority
BR
Brazil
Prior art keywords
pld
treatment
combination
corona virus
cov
Prior art date
Application number
BR112022016653A
Other languages
English (en)
Inventor
Izquierdo-Useros Nuria
Vergara-Alert Júlia
Avilés Marín Pablo
Losada González Alejandro
María Fernández Sousa-Faro José
Fudio Muñoz Salvador
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR112022016653A2 publication Critical patent/BR112022016653A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PLD PARA USO EM COMBINAÇÃO NO TRATAMENTO DE CORONAVÍRUS. A presente invenção refere-se ao uso de PLD com ainda um ou mais agentes antivirais CoV no tratamento de infecção de coronavírus (CoV).
BR112022016653A 2020-03-02 2021-03-02 Pld para uso em combinação no tratamento de coronavírus BR112022016653A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382821 2020-09-17
PCT/EP2021/055131 WO2021175823A1 (en) 2020-03-02 2021-03-02 Pld for use in combination in the treatment of coronavirus

Publications (1)

Publication Number Publication Date
BR112022016653A2 true BR112022016653A2 (pt) 2022-10-11

Family

ID=74758810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016653A BR112022016653A2 (pt) 2020-03-02 2021-03-02 Pld para uso em combinação no tratamento de coronavírus

Country Status (13)

Country Link
US (1) US20230158103A1 (pt)
EP (1) EP4114434A1 (pt)
JP (1) JP2023517194A (pt)
KR (1) KR20220150348A (pt)
CN (1) CN115243703A (pt)
AU (1) AU2021231521A1 (pt)
BR (1) BR112022016653A2 (pt)
CA (1) CA3169528A1 (pt)
CO (1) CO2022014044A2 (pt)
IL (1) IL296067A (pt)
MX (1) MX2022010920A (pt)
PE (1) PE20230302A1 (pt)
WO (1) WO2021175823A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4238560A4 (en) * 2020-10-30 2024-09-18 Senju Pharma Co THERAPEUTIC AGENT AGAINST COVID-19
CN114796177B (zh) * 2022-06-27 2022-09-30 广州国家实验室 抗冠状病毒药物和应用
CN117618452B (zh) * 2022-08-29 2024-08-23 山东如至生物医药科技有限公司 一种药物组合物及其制备方法和其在抗病毒方面的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину

Also Published As

Publication number Publication date
JP2023517194A (ja) 2023-04-24
WO2021175823A1 (en) 2021-09-10
EP4114434A1 (en) 2023-01-11
MX2022010920A (es) 2022-11-30
IL296067A (en) 2022-11-01
CN115243703A (zh) 2022-10-25
US20230158103A1 (en) 2023-05-25
KR20220150348A (ko) 2022-11-10
AU2021231521A1 (en) 2022-10-06
CO2022014044A2 (es) 2022-11-29
PE20230302A1 (es) 2023-02-13
CA3169528A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
BR112022016653A2 (pt) Pld para uso em combinação no tratamento de coronavírus
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR112022017986A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112022017243A2 (pt) Lactoferrina para uso oral com ação antiviral
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
BR112015032091A2 (pt) variedade de artigos absorventes descartáveis para ajuste em uma ampla faixa de usuários
BRPI0720569B8 (pt) compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
WO2022217154A3 (en) Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses
ECSP099447A (es) Derivados indólicos con anillo unido en las posiciones 4,5 y sus métodos de uso
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
BRPI0814725B8 (pt) uso da composição antiviral
BR112023023223A2 (pt) Degradadores de cdk2 e usos dos mesmos
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
BRPI0516542A (pt) composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária
BR112021025630A8 (pt) Moléculas novas
AR120048A1 (es) Uso de virus oncolíticos para el tratamiento del cáncer
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
BR112017015340A2 (pt) uso de taurina na prevenção e/ou tratamento de doenças induzidas por vírus do gênero coronavírus e/ou gênero rotavírus
BR112022018284A2 (pt) Azd1656 para uso no tratamento de pneumonite e/ou miocardite causada por coronavírus
BR112022019679A2 (pt) Composição

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]